Sterile Powder Fill Lines for Ampicillin Sodium and Sulbactam Sodium Operate Under Aseptic Constraint

The sterile injectable presentation is filled as a dry crystalline powder containing ampicillin sodium equivalent to 1.0 g ampicillin and sulbactam sodium equivalent to 0.5 g sulbactam per vial, maintaining the 2:1 ampicillin-to-sulbactam activity ratio required for intravenous and intramuscular reconstitution. Aseptic processing is mandatory because beta-lactam hydrolysis in aqueous solution and solid-state thermal degradation preclude terminal sterilization; the powder fill is executed in an ISO 14644-1 Class 5 isolator line under EU GMP Annex 1 constraints, with the two sterile sodium salts blended in a low-shear tumble blender at 60% vessel volume to reduce segregation. The blend is discharged into a servo-driven auger powder filler equipped with 100% in-process gravimetric check weighing, and the filled vials are stoppered under a filtered nitrogen purge. Particle size distribution of the sterile blend is monitored by laser diffraction, and the D90 acceptance limit is linked to reconstitution time in Sterile Water for Injection. Reconstitution with Sterile Water for Injection produces a solution pH in the range of 8.0–10.0; the sodium content contributes to tonicity, and the reconstituted solution is further diluted in 0.9% Sodium Chloride Injection for infusion. Potency and purity are confirmed by USP <71> sterility testing, USP <85> bacterial endotoxin limits, USP <788> particulate matter, and USP <921> moisture determination. Elemental impurity levels are controlled under ICH Q3D, and batch release follows 21 CFR 211.165 with in-process controls executed under 21 CFR 211.110. The critical processing boundary is hydrolytic instability after reconstitution: the solution must be used within the approved storage time at controlled room temperature, and dextrose-containing diluents are avoided for extended infusion because the beta-lactam ring degrades faster in dextrose solutions than in saline.

On oral granule lines manufacturing dry suspension sachets, the sodium salt pair is processed by non-aqueous wet granulation to limit premature beta-lactam hydrolysis before the dry product is reconstituted. Anhydrous ethanol is sprayed into a high-shear mixer granulator containing ampicillin sodium, sulbactam sodium in a 2:1 activity ratio, sucrose or sorbitol, sodium citrate buffer, and xanthan gum; the wet mass is then dried in a top-spray fluid bed dryer fitted with a bag-filter air distribution plate, and a 0.8 mm sieve is used for final granule size reduction. Residual solvent is controlled under ICH Q3C Class 3 guidance, and the dried granules are packed in aluminum foil sachets with a desiccant pouch. The operational limitation is explicit: sulbactam sodium has poor oral absorption, so granules prepared directly from the sodium salt pair do not reproduce the systemic kinetics of injectable ampicillin/sulbactam; this presentation is reserved for local gastrointestinal delivery, extemporaneous compounding, or veterinary oral administration where pharmacokinetic differences are acceptable. Dissolution is evaluated by USP <711> using an aqueous buffer medium selected to reflect gastric pH, and microbial quality is controlled under USP <61> and USP <62>.

When Direct Tablet Compaction of the Sodium Salt Pair Is Evaluated

Direct compression of ampicillin sodium and sulbactam sodium in tablet production is constrained by hygroscopicity, low bulk density, and the poor oral bioavailability of unchanged sulbactam sodium. A tablet formulation based solely on the sodium salts is therefore evaluated only for non-systemic local gastrointestinal delivery or veterinary use; systemic oral ampicillin/sulbactam therapy is normally achieved by converting the API pair into the mutual prodrug sultamicillin tosylate before granulation and compression. In a low-humidity tableting suite held below 30% RH, a dry blend of the sodium salts at a 2:1 activity ratio with anhydrous dibasic calcium phosphate, microcrystalline cellulose, and crospovidone can be processed on a rotary tablet press fitted with 10 mm flat-faced bevel-edge punches; published production-scale data for this direct-salt configuration are limited because commercial oral tablets rely on the prodrug. Film coating with hydroxypropyl methylcellulose or polyvinyl alcohol in a perforated pan coater reduces moisture uptake and masks the bitter taste of the beta-lactam ingredients. Content uniformity is controlled by USP <905>, dissolution by USP <711>, and residual solvent burden from prodrug synthesis by ICH Q3C. The boundary condition is narrow: if unprotected sodium salt compacts are exposed to ambient humidity above 30% RH, powder caking and beta-lactam potency loss occur; pre-dried excipients and aluminum-aluminum blister packaging are required.

Low-humidity powder handling governs capsule filling of granules containing the ampicillin/sulbactam pair, because water uptake reduces flow and accelerates beta-lactam hydrolysis. Automatic capsule filling machines using dosator or tamping-pin technology operate with hard gelatin capsules maintained at 35%–45% RH to prevent brittleness, while the granule feed hopper is held below 25% RH through localized dry-air purge. This split-humidity control is a recognized production bottleneck: the operator must balance capsule shell flexibility against granule moisture uptake. Granules are blended with 0.5% colloidal silicon dioxide as glidant and sodium stearyl fumarate as lubricant to avoid excessive shear on the beta-lactam crystals. Fill weight is monitored by automatic in-process weighing, and content uniformity is assessed by USP <905>. Finished capsules are packaged in HDPE bottles with desiccant canisters or cold-form aluminum-aluminum blisters; water vapor transmission of the blister foil is specified by ASTM F1249. If the capsule contains sultamicillin tosylate granules rather than the unmodified sodium salts, the bioavailable ampicillin/sulbactam ratio in systemic circulation follows the prodrug hydrolysis stoichiometry, not the simple 2:1 sodium salt input ratio.

Why Is the 2:1 Input Ratio Not Necessarily the Bioavailable Ratio in Oral Granule and Capsule Products?

The 2:1 ampicillin-to-sulbactam activity ratio in the sterile injectable powder is maintained because both sodium salts are administered directly into the systemic circulation after dissolution. In oral dosage forms, the same ratio is not automatically preserved when unmodified sulbactam sodium is poorly absorbed from the gastrointestinal tract; consequently, oral systemic therapy uses the mutual prodrug sultamicillin tosylate, which is manufactured from ampicillin sodium and sulbactam sodium as starting materials. The ester prodrug is cleaved by intestinal esterases after absorption, releasing ampicillin and sulbactam in a defined molar ratio that may differ from the 2:1 mass input of the sodium salts. For this reason, tablet and capsule formulations must be labelled on the basis of ampicillin and sulbactam equivalents, not on the weight of ampicillin sodium and sulbactam sodium charged into the granulation. Analytical release includes assay of both actives by a stability-indicating method, with acceptance ranges consistent with USP <905> content uniformity and the approved product specification. Published data for direct oral granules of the unmodified sodium salts are limited, and the route is not interchangeable with injectable therapy without bioequivalence data.